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We aimed to prepare and investigate microparticles with the
varying contents of calcium gelling ion, loaded with phenytoin,
a standard antiepileptic agent, in its acidic form. Two differ-
ent methods of alginate-based microparticles preparation were
used: with and without treatment with chitosan. Furthermore, two
standard procedures, the one-stage and the two-stage, were ap-
plied. Microparticle size of 12 one-stage formulations ranged from
466 to 636 µm. Both types of formulations, chitosan-treated and
nontreated, appeared to be highly loaded with the model drug
(91–96%). The chitosan-coated alginate-based microparticles pre-
pared by the one-stage procedure exhibited kinetics of phenytoin
liberation comparable to a similar sustained release system that
had been tested at pH 6.8, as published earlier. As the gel erosion of
alginate-based microparticles should be potentiated by the higher
pH (used in the present study at pH 7.4), the most favorable of 12
formulations, with the liberation half-time of about 2 hr, seemed
to be eligible for further modifications. Counterintuitively, the ap-
plied two-stage procedure did not appear to beneficially affect the
dissolution behavior of phenytoin when tested in two formulations,
which makes further modifications necessary.
Keywords Alginate-Chitosan Microparticles, Phenytoin, Prepara-
tion, Release Behavior
The alginate-based microparticles have been widely inves-
tigated in a large array of applications, such as enzyme im-
mobilization, immunoisolation in cell transplantation, and drug
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release systems (Gaserod, Sannes, and Skjak-Braek 1999). Such
versatility is based on natural source, easy handling, and bio-
compatibility of alginates (Buthe, Hartmeier, and Ansorge-
Schumacher 2004). Alginate is a family of polysaccharides com-
posed of α-L-guluronic acid (G) and β-D-mannuronic acid (M)
residues, arranged in homopolymeric (MM, GG) as well as het-
eropolymeric blocks (MG). It has been well established that
the monomer composition affects drug release from the differ-
ent formulation systems (Takka and Acarturk 1999; McDowell
1986). Alginates with high mannuronic acid content are appro-
priate for thickening applications, whereas alginates with a high
level of guluronic acid are the best for forming gels (Takka and
Acarturk 1999).
Concerning the sustained release systems, gel erosion of
alginate-based microparticles due to presence of chelators such
as phosphate, lactate, or citrate or nongelling cations like sodium
or magnesium, imposes a significant problem, since it accel-
erates the release of a drug. Therefore, there is need for a
stabilizing agent that can be a membrane forming polycation
bound to the alginate gel by electrostatic interactions. One
such agent is chitosan, a natural linear biopolyaminosaccha-
ride, obtained by alkaline deacetylation of chitin (Roberts 1992).
Chitin is a straight homopolymer composed of β-(1,4)-linked
N -acetyl-glucosamine units, whereas chitosan comprises a se-
ries of copolymers of glucosamine and N -acetyl-glucosamine
(Kas 1997; Singla and Chawla 2001; Kato 2003). Chitosan has
one primary amino and two free hydroxyl groups for each C6
building unit. Due to the easy availability of free amino groups in
chitosan, it carries a positive charge and thus reacts with different
negatively charged surfaces and polymers (Sinha et al. 2004).
There are numerous variations in procedures and materials
applied during the production of microparticles with a complex
coacervate alginate-chitosan membrane and a solid alginate gel
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core. However, the two principal modes are one-stage and two-
stage procedures. In the one-stage procedure, a complex coac-
ervate membrane is formed at the interface between the alginate
and chitosan solutions when the alginate solution is dropped di-
rectly into the solution of chitosan. This yields particles with a
complex alginate-chitosan membrane surrounding a liquid al-
ginate core. Gelling of the core is achieved by having calcium
chloride in chitosan solution either during the formation of the
particles (Huguet, Neufeld, and Dellacherie 1996; Huguet et al.
1994; Lee, Park, and Ha 1997; Overgaard et al. 1991) or by treat-
ing the liquid core particles with the salt after the membrane has
been formed (Huguet et al. 1994).
The two-stage procedure comprises formation of calcium al-
ginate beads, followed by a membrane forming stage when the
beads are suspended in a solution of polycation (Lim and Sun
1980). The amount of chitosan bound to the alginate beads de-
pends on several factors (Gasserod, Smidsrod, and Skjak-Braek
1998). First, the choice of producing method clearly limits the
amount of bound chitosan. If the capsules are made by a one-
stage procedure, only low amounts of chitosan could be bound.
This is probably because chitosan binds to the surface only and
creates a membrane with such small pores they prevent further
diffusion of chitosan into the beads, and subsequent binding onto
the gel network is restricted. In the two-stage procedure, more
chitosan can be bound both onto the surface of the bead and in
the interior of the gel network while suspending calcium alginate
beads in a solution of chitosan. Hence, the two-stage procedure
may result in binding 100 times more chitosan than with the one-
stage procedure. These high chitosan contents are only obtained
for the most porous gels with the chitosan of average molecular
weight less than 20,000.
High porosity is achieved by selecting an alginate with a high
ratio of α-L-guluronic acid to β-D-mannuronic acid residues, by
including gelling calcium ions in the chitosan solution, and/or
by making the beads homogeneous (Gasserod, Smidsrod, and
Skjak-Braek 1998). Homogeneity here refers to the alginate con-
centration gradient through the cross-section of the bead. In an
inhomogeneous bead, the alginate concentration at the bead sur-
face may be 10 times higher than in the center (Skjak-Braek,
Grasdalen, and Smidsrod 1989).
The objective of the study was to prepare and evaluate mi-
croparticles with varying contents of calcium gelling ion and
chitosan, loaded with phenytoin in its acidic form, to improve
drug release. The model substance phenytoin has been well es-
tablished as a standard antiepileptic agent. The extended-release
formulations of antiepileptics decrease daily fluctuations and
simplify treatment of this chronic condition. Such commercial
formulations with phenytoin sodium appear to be well designed,
with one possible shortcoming. That concern deals with the po-
tential for irregular absorption that appears to occur particularly
in the case of elderly patients (Pellock et al. 2004). Besides
the wanted well-controlled release, an additional benefit of the
present investigation might be manufacturing in environmen-
tally friendly conditions.
MATERIALS AND METHODS
Manugel GHB, medium viscosity sodium alginate with high
guluronic acid (“high G”) content was kindly donated by ISP
(International Specialty Products, NJ, USA). Phenytoin was
provided by Fluka (Neu-Ulm, Germany). Chitosan, high and
low molecular weight (degree of deacetylation, >75% and
75–85%, respectively), was purchased from Aldrich (Milwau-
kee, WI, USA). Calcium chloride was obtained from Merck
KGaA (Darmstadt, Germany).
Microparticles Preparation
Microparticles were prepared according to the one-stage pro-
cedure using a custom made air-jet device. Approximately 7 ml
of 2% phenytoin suspension (bubble free) in 2% aqueous solu-
tion of alginate (drug:polymer ratio = 1:1) was extruded through
a 20-gauge needle at a rate of 120 ml/hr into 70 ml of a gelling
medium that consisted of aqueous solution of different concen-
trations of calcium chloride and chitosan. pH value of gelling
medium was adjusted to 5.5 with acetate buffer. The laminar air
flow in coaxial cylinder, pointed to the tip of the needle pro-
ducing small droplets, was constant (1200 l/hr). The prepared
microparticles were allowed to harden for 1 hr, after which they
were collected, washed, and dried at room temperature for 72 hr.
The 12 different formulations (F1–F12) of inhomogeneous mi-
croparticles were made according to this procedure (Table 1).
In case of the two-stage procedure, after 30 min of hardening
of the microparticles in gelling medium with different concen-
trations of calcium chloride, they were transferred without wash-
ing to a solution of 0.2% (w/w) chitosan (pH adjusted to pH 5.5
with acetate buffer). Chitosan solutions also contained 0.3M of
calcium chloride. According to this procedure, two additional
formulations, a homogeneous one with low molecular weight
chitosan (F7a) and an inhomogeneous one with high molecular
TABLE 1
Composition of model formulations of inhomogeneous
microparticles prepared according to the one-stage procedure
CaCl2 concentration Chitosan concentration
Formulation (%, w/w) (%, w/w)
F1 0.5 —
F2 1.0 —
F3 2.0 —
F4 0.5 0.1
F5 1.0 0.1
F6 2.0 0.1
F7 0.5 0.2
F8 1.0 0.2
F9 2.0 0.2
F10 0.5 0.4
F11 1.0 0.4
F12 2.0 0.4
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weight chitosan (F7b), were prepared. Homogeneity of the mi-
croparticles was achieved by including 200 mM of NaCl in the
gelling medium (Skjak-Braek et al. 1989).
Microparticles Size Determination
The particle sizes of 50 microparticles were measured with
Motic digital microscope DMB3-223ASC and Motic Images
Plus v.2.0 software for each formulation and the mean particle
size was determined.
Drug Assay (Drug Loading Determination)
Determination of phenytoin in microparticles was performed
using RP-HPLC method after microparticles were broken with
the aid of ultrasonication in 0,1 M NaOH for 15 min, with subse-
quent centrifugation at 4000 rpm for 5 min. Phenobarbitone was
used as an internal standard. The column used was Zorbax SB-
C18, 250 × 4, 6 mm, 5 µm. Composition of mobile phase was
ethanol:water:0,5% triethanolamine in ratio 40:59,5:0,5 (v/v/v),
respectively. pH of mobile phase was adjusted to 3.0 with 85%
ortophosphoric acid. Chromatography was conducted at ambi-
ent temperature at a flow rate of 1.0 ml/min. The absorbance
of each sample was determined spectrophotometrically at 228
nm using Agilent 1100 Series variable wavelength ultraviolet
detector. All determination tests were performed in triplicate.
Drug Release Studies
The release of phenytoin from microparticles was measured
quantitatively on an automatic sampling and analysis system
Erweka DT 800 (Erweka GmbH, Heusenstamm, Germany) us-
ing the rotating basket method at 100 rpm with the temperature
maintained at 37◦C, in 900 ml phosphate buffer (pH 7,4 USP23).
The obtained samples were mixed with solution of internal stan-
dard and phenytoin content was determined as explained un-
der Drug Assay section. All release tests were performed in
triplicate.
FIG. 1. Particle size of alginate (F1–F3) and alginate-chitosan microparticles
(F4–F12).
FIG. 2. Photomicrograph of formulations F3 before (left) and after drying
(right).
RESULTS AND DISCUSSION
Microparticles Size Determination
Recorded microparticle sizes were in the range of
466.2 ± 14.8 to 635.5 ± 6.2 µm. Although statistical analysis
(not shown) pointed to some inhomogeneity in mean diameters
of microparticles, the range of obtained values does not suggest
reliable influence of chitosan on microparticle size (Figure 1),
which is in good accord with the results described previously
(Takka and Acarturk 1999).
However, far different from alginate-based formulations
(Figure 2), presence of chitosan tended to distort the spherical
shape of microparticles during both the manufacturing and the
drying phase (Figure 3). This observation was not at all unex-
pected (Shu and Zhu 2002). In the one-stage procedure, with chi-
tosan of high molecular weight present in the gelling medium,
it has been observed that droplets of alginate are not able to
break easily through the surface (Gaserod et al. 1999). This
may explain in part the nonspherical shape of microparticles of
formulations with higher chitosan concentration. Moreover, the
spherical shape of alginate and alginate-chitosan microparticles
(up to 0.2% of chitosan) in the wet state was usually lost after
drying, especially for those prepared with low alginate concen-
tration (Shu and Zhu 2002). This indicates that the integrity of
alginate microparticles, as well as integrity of alginate-chitosan
membrane, may be compromised in the drying process. Finally,
FIG. 3. Photomicrograph of formulations F12 before (left) and after drying
(right).
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TABLE 2
Drug loading of 12 (F1–F12) studied model formulations
Formulation Drug loading (%)
F1 92.84 ± 2.97
F2 95.33 ± 3.09
F3 95.50 ± 3.14
F4 96.02 ± 4.10
F5 96.25 ± 2.08
F6 96.34 ± 1.99
F7 90.63 ± 3.87
F8 93.91 ± 4.58
F9 95.88 ± 2.73
F10 96.15 ± 3.79
F11 93.01 ± 2.88
F12 95.12 ± 3.95
a trend of improving the sphericity of dried microparticles with
the increase of alginate concentration also has been noticed (pic-
tures not shown).
Drug Assay
Both types of formulations, chitosan-treated and nontreated,
appeared to be highly loaded with the model drug (Table 2).
The drug contents of the dried microparticles were determined
to be 90.63–96.34%. No clear relationship between the drug
loading and concentration of calcium chloride and chitosan was
found, neither was any influence of mere chitosan presence
detected.
Furthermore, it appeared that the recorded morphological
changes did not affect encapsulation efficiency. Measuring the
phenytoin particles in alginate suspension showed that average
particle perimeter was 44.0 µm (Figure 4). Along with its poor
solubility in aqueous media, such a high perimeter probably pre-
vented exit of phenytoin through the pores of instantaneously
formed microparticles. This may be a part of explanation for
such a high loading capacity.
FIG. 4. Photomicrograph of phenytoin particles in alginate suspension.
Drug Release Studies
Figure 5 depicts the phenytoin release profiles from all algi-
nate and alginate-chitosan microparticle formulations manufac-
tured in the one-stage procedure. The times for 50% and 90% of
drug to be released (t50% and t90%, respectively), as the param-
eters suitable for comparing the different formulations (Takka
and Acarturk 1999; Sankalia et al. 2005), are shown in Table 3.
We found that the influence of chitosan coating on phenytoin
release cannot be clearly deduced.
It has been reported that the alginates rich in guluronic acid
form more rigid gels, which are less prone to erosion and the
drug release would be slower. Murata et al. (1993) found that
the release of drug from M-rich alginate gels was slightly faster
than that from G-rich alginate gels, despite similarity in their
molecular weights. The gelation takes place by forming egg-
box junctions to associate the metal ions with the GG blocks
of the alginate chain (McDowell 1986; Tonessen and Karslen
2002). Being a polyelectrolyte, alginate can exhibit swelling
properties that are sensitive to pH, ionic strength, and specific
ionic composition of the medium (Ostberg, Lund, and Graffner
1994). These factors also may influence the release properties
of alginate-based formulations.
Also, the polyion complexation between chitosan and an-
ionic polymers depends on the pH value of the media, the ionic
strength, and temperature (Takahashi et al. 1990). Polk et al.
(1994) investigated the effect of the pH of gelling medium con-
taining chitosan on microparticle strength and flexibility and
reported that the strength and flexibility of the microparticle
membrane were maximal as the pH of the chitosan solution
increases to 5.5. Furthermore, for drugs of poor water solubil-
ity encapsulated into alginate-chitosan microparticles, molecu-
lar weight and viscosity of alginates should not affect the drug
release (Takka and Acarturk 1999).
Taking into consideration these suggestions, 3 formulations
were prepared (F1 through F3) using different concentrations of
TABLE 3
Times for 50% and 90% of the drug to be released, t50% and
t90%, respectively
Formulation t50% (min) t90% (min)
F1 72,98 157,54
F2 63,50 137,85
F3 50,79 125,00
F4 83,45 163,45
F5 68,29 146,88
F6 57,12 147,01
F7 114,79 219,50
F8 59,62 143,30
F9 53,48 130,55
F10 76,48 166,77
F11 68,02 155,93
F12 34,17 129,41
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FIG. 5. Release profiles of phenytoin from alginate and alginate-chitosan microparticles.
calcium chloride and alginate of medium viscosity characterized
with high G content and 9 formulations (F4 through F12) with
different concentrations of chitosan and calcium chloride using
the same type of alginate. In addition, the pH of all gelling
solutions was adjusted to pH 5.5.
In general, the addition of a given concentration of chitosan
tended to delay the release of drug from the high G alginate-
made microparticles (Figure 6a). The t50% value of F1 formu-
lation, prepared only with 0,5% of calcium chloride present in
the gelling medium, was 73 min, whereas t50% value of F7 for-
mulation, prepared with 0,5% of calcium chloride and 0,2% of
chitosan in gelling medium was 115 min.
For the given concentrations of calcium chloride present in
the gelling medium, phenytoin release from alginate-chitosan
microparticles decreased with the addition of chitosan to the
gelling medium, especially for 0.2% of chitosan (Figure 6b).
Similar results, for small molecular weight drugs of poor sol-
ubility in aqueous media, macromolecular drugs, and small
molecular weight drugs with high solubility, were reported
earlier (Takka and Acarturk 1999; Sezer and Akbuga 1999a,
1999b).
We observed, unexpectedly, that the increase of chitosan con-
centration over 0.1% tended to accelerate phenytoin release,
except for formulation F7, prepared with 0.5% calcium chlo-
ride and 0.2% chitosan present in the gelling medium. For this
formulation, a distinct delay in release of phenytoin from mi-
croparticles, compared with all other formulations, was observed
(Figure 6b). In some cases, chitosan coating markedly acceler-
ated phenytoin release compared with microparticles prepared
only from alginate. For example, t50% values for formulation
F3 prepared with 2.0% of calcium chloride and with no chi-
tosan present in the gelling medium was 51 min, compared with
formulation F12, prepared with 2.0% of calcium chloride and
0.4% of chitosan, with t50% of 34 min.
However, the difference between t90% values of these formu-
lations was not so distinct. The similar phenomena were reported
earlier for a water soluble dye, brilliant blue, where release media
was 0.9% sodium chloride and 0.1 M phosphate buffer as well,
especially in the case of dried microparticles and in some cases
of nondried microparticles, made in single stage procedure. The
authors attributed these phenomena to destroying the integrity of
chitosan-alginate complex membrane during the drying process
(Shu and Zhu 2002).
The influence of calcium chloride concentration on phenytoin
release also was examined (Figure 6c). The t50% and t90%values
of formulations F1–F3 made with 0.5%, 1.0%, and 2.0% of cal-
cium chloride present in gelling medium were 73, 64, 51 and
158, 138, and 125 min, respectively. They found that an in-
creased drug release occurs while increasing calcium chloride
concentration. Similar data were reported earlier (Sezer and Ak-
buga 1999a).
To further improve the liberation profile of phenytoin, two
different modifications of the formulation with best kinetics of
drug release, F7, were explored. Namely, we showed that in-
tegrity of microparticles in solutions against osmotic pressure
and sequestrants could be significantly improved if more chi-
tosan is bound to the alginate. This could be achieved if mi-
croparticles are made according to the two-stage procedure,
with addition of calcium ions to the gelling medium along
with chitosan and by making them homogeneous (Gaserod et
al. 1999). Based on this procedure, the first modification, F7a,
was made. Furthermore, it has been postulated that, on swelling
in dissolution medium, the integrity of microparticles would be
maintained with the pores small enough to keep the relatively
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FIG. 6. (a) Release profiles of phenytoin from alginate and alginate-chitosan microparticles. (b) Effect of chitosan concentration on release characteristics of
alginate-chitosan microparticles. (c) Effect of calcium chloride concentration on release characteristics of alginate and alginate-chitosan microparticles.
FIG. 7. Effect of preparation procedure on release characteristics of alginate-chitosan microparticles. F1 and F7 are prepared according to the one-stage procedure;
F7a and F7b, according to the two-stage procedure.
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large particles of phenytoin inside, thereby further slowing its
release.
The second modification F7b was made having in mind that
permeability of microparticles can be reduced by preparing them
to be inhomogeneous, also according to the two-stage procedure,
but with high molecular weight chitosan (Gaserod et al. 1999).
The rationale for this second approach is that microparticles with
improved stability and reduced permeability further slow down
the release of drug in dissolution medium.
Figure 7 shows the release profile of phenytoin from F7a and
F7b formulations compared with basic formula F7 and to F1,
made only with calcium chloride and with no chitosan present
in gelling medium. It can be seen that both modifications ac-
tually further increase the release of phenytoin, with increase
that is more pronounced for formulation F7b. This was not to-
tally unexpected since Shu and Zhu (2002) showed that chitosan
coating accelerated release of the water soluble dye brilliant blue
in 0.10 M phosphate buffer from nondried microparticles, com-
pared with those made only with alginate, especially when the
single stage procedure was used. Here, in contrast with find-
ings by Shu and Zhu (2002), the microparticles prepared ac-
cording to the single-stage procedure exhibited more favorable
release profile in phosphate buffer compared with formulations
F7a and F7b, prepared according to the two-stage procedure. At
least partly, this may be seen as an unfavorable influence of the
drying process on susceptibility of the microparticles prepared
according to the two-stage procedure to the phosphate buffer. Al-
ternatively, the difference in the model drug or preparation pro-
cedure used may explain in part this discordance. For instance,
as a consequence of different manufacturing devices employed,
mean particle sizes were 6-fold greater in Shu and Zhu (2002)
than in our experiment. Also, concentrations of calcium chlo-
ride in chitosan solutions were different, whereas NaCl (added
to prepare homogeneous microparticles) was present only in our
gelling medium.
CONCLUSION
The performed one-stage procedure yielded particles of
nonspherical shape on drying process, with the sphericity im-
proving with the increase of alginate concentration, without re-
liable influence of chitosan on microparticle size. All studied
formulations were of very high model drug loading, with no in-
fluence of the calcium chloride or chitosan concentration on this
parameter.
Increasing calcium chloride resulted in enhanced phenytoin
release, whereas the influence of chitosan on the model drug
release from particles made according to the one-stage proce-
dure was complex and not so clear-cut. In some cases, chitosan
coating markedly accelerated phenytoin release compared with
the nontreated microparticles, which could be attributed partly
to destroying the integrity of chitosan-alginate complex surface
layer during the drying process. In other cases, the release of
phenytoin held within the high G alginate-made chitosan-treated
microparticles incubated in phosphate buffer was delayed com-
pared with the nontreated ones, presumably due to the sup-
pressed erosion of chitosan-reinforced calcium-induced alginate
gel network. The delay was marked in the case of formulation F7,
with the t50% value of 115 min, making it eligible for further mod-
ifications. However, modifications of F7 formulation according
to the two-stage procedure did not appear to beneficially affect
the release behavior of phenytoin, and further modifications are
needed.
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